- Company
- Roche: Fast listing was all about improving patient access
- by Eo, Yun-Ho Nov 2, 2020 06:13am
- An anticancer treatment specializing pharmaceutical company, Roche has been viewed to stand relatively “aloof” from seeking the health insurance reimbursement. But now Roche seems to be picking up its speed. Their last two years have been different; the company successfully expanded the reimbursement on targeted therapy Alecensa in anap
- Company
- 19 Korean companies partially win Forxiga patent dispute
- by Kim, Jin-Gu Nov 2, 2020 06:13am
- A South Korean court ruled in favor of the generic companies in an appeal case for a patent dispute on an antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Forxiga (dapagliflozin). The original company AstraZeneca lost another patent litigation in a higher court after losing from the Intellectual Property Trial and Appeal Board
- Company
- Boryung recorded the largest quarterly sales performance
- by An, Kyung-Jin Oct 30, 2020 05:54am
- Boryung's quarterly performance improved even amid the economic downturn caused by COVID-19. The growth of new drugs introduced by multinational pharmaceutical companies, centering on Kanarb Family developed with their own technology, has contributed to the improvement of the performance of the Prescription drugs division. Boryung announc
- Company
- Novartis "No more order suspension for Myfortic 3rd trial"
- by Kim, Jin-Gu Oct 30, 2020 05:54am
- Although Novatis took an appeal case on the pricing reduction order for Myfortic Enteric Coated Tablet to the Supreme Court, the company has reportedly decided to not request to halt the administration order. Even if the South Korea’s Ministry of Health and Welfare (MOHW) issues an order to bring down the drug pricing according to the se
- Company
- Interview: More options in CDK4/6 inhibitor-Faslodex
- by Eo, Yun-Ho Oct 29, 2020 05:52am
- The emergence of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in treatment of patients with human epidermal growth factor receptor 2-negative (HER2-) breast cancer has brought a change in treatment pattern. Technically, chemotherapy was the only option in the hormone receptor-positive (HR+) and HER2- breast cancer. Ibrance (palbocic
- Company
- MSD has appointed So-eun Kim as the first CEO of Organon
- by Oct 29, 2020 05:51am
- MSD announced on the 27th that it has appointed So-eun Kim (49 years old), currently managing director of MSD Korea, as the new CEO of Organon & Co, which will be newly established through the spin-off in the first half of 2021. Organon & Co's term of office begins on February 1, 2021, when the division of the company in Korea is complete
- Company
- Evrysdi is expected to enter Korea
- by Eo, Yun-Ho Oct 28, 2020 06:03am
- The third SMA treatment is expected to enter Korea following Biogen's Spinraza approved in 2017 and Novartis' Zolgensma, which is currently undergoing approval review. According to related industries, Roche also submitted an application for Evrysdi (Risdiplam) to the MFDS after approval from the US FDA in August. All of these drugs are t
- Company
- Sanofi launches Dupixent '200mg' in Korea
- by Oct 28, 2020 06:02am
- Sanofi-Aventis Korea (CEO Kyung-eun Bae) announced that it will release Dupixent PFS 200mg (Dupilumab), a biologic drug for atopic dermatitis and asthma on the 26th. Accordingly, Dupixent is available in two doses, 200mg in addition to the 300mg previously released. According to the MFDS, Dupixent 200mg can be used for moderate-severe
- Company
- Ilyang's leukemia treatment Supect, approved by Russian GMP
- by Oct 28, 2020 06:02am
- The factory that manufactures Ilyang's Supect has passed the GMP (Manufacturing, Processing, Packing or Holding of Drugs) due diligence conducted by the Russian government. According to the pharmaceutical industry on the 26th, the Ministry of Industry and Trade of Russia determined that Ilyang’s plant located in Jecheon-si, Chungcheongbuk
- Company
- Tecentriq as 1st reimbursed immunotherapy for TNBC and HC
- by Eo, Yun-Ho Oct 27, 2020 06:12am
- An immunotherapy Tecentriq (atezolizumab) is seeking for the National Health Insurance (NHI) reimbursement in treating patients with either triple-negative breast cancer (TNBC) or hepatocellular carcinoma. A pharmaceutical industry source reported Roche Korea has recently submitted an application to expand reimbursement for indication to
